PCSK9 News
298 views | +0 today
Follow
PCSK9 News
PCSK9: the new target to manage uncontrolled LDL [Disclaimer: This is a personal page; however, my company (WCG) currently works for Sanofi on SAR236553]
Curated by Manu Field
Your new post is loading...
Your new post is loading...
Scooped by Manu Field
Scoop.it!

New Cholesterol-Lowering Drugs Will Test the Future Healthcare System - Forbes

New Cholesterol-Lowering Drugs Will Test the Future Healthcare System - Forbes | PCSK9 News | Scoop.it
The American College of Cardiology (ACC) meeting is in full swing this week in Chicago and much of the early buzz being generated is around a new class of LDL cholesterol-lowering drugs known as proprotein converase subtilisin/kexin type 9 (PCSK-9)...
more...
No comment yet.
Scooped by Manu Field
Scoop.it!

Nick Denis trades in laboratory for the octagon

Nick Denis trades in laboratory for the octagon | PCSK9 News | Scoop.it
Globe and MailNick Denis trades in laboratory for the octagonGlobe and MailHe was also excelling at school, publishing a number of papers on his work on the PCSK9 protein – which helps regulate the amount of cholesterol in the bloodstream – and...
more...
No comment yet.
Scooped by Manu Field
Scoop.it!

MM&M Therapeutic Focus: Cardiovascular - Medical Marketing and Media

MM&M Therapeutic Focus: Cardiovascular - Medical Marketing and Media | PCSK9 News | Scoop.it

"2011's five CV arrivals—more than in any of the past seven years—bode well for potential CV blockbusters moving through pharma pipelines. These include cholesteryl ester transfer protein (CETP) inhibitors, designed to raise HDL or “good” cholesterol, and PCSK9 inhibitors, which may work with statins to lower uncontrolled lipids seen in a third of statin-treated patients"

more...
No comment yet.
Scooped by Manu Field
Scoop.it!

Why LDL cholesterol is atherogenic - Irish Medical Times

Prof Gerald H Tomkin provides an overview of the role played by LDL and the correlation between LDL cholesterol levels and atherosclerotic risk

more...
No comment yet.
Scooped by Manu Field
Scoop.it!

Long-Term Safety and Tolerability of SAR236553 (REGN727) in ...

Primary Objective: To evaluate the long-term safety and tolerability of SAR236553 (REGN727) in high cardiovascular risk patients with hypercholesterolemia not a...
more...
No comment yet.
Scooped by Manu Field
Scoop.it!

Trial watch: PCSK9 antibody reduces LDL cholesterol | Knowledge of Medicine

Trial watch: PCSK9 antibody reduces LDL cholesterol | Knowledge of Medicine | PCSK9 News | Scoop.it
Trial watch: PCSK9 antibody reduces LDL cholesterol - http://t.co/dEMUWO7c...
more...
No comment yet.
Scooped by Manu Field
Scoop.it!

Analyst Is Skeptical Of Rival Company's Warnings About Regeneron

Backers of Isis & Regeneron feud over PCSK9 prospects

more...
No comment yet.
Scooped by Manu Field
Scoop.it!

Isis Chief Says Safety Concerns Could Slow His Competitors

Stan Crooke says the FDA could delay the development of cholesterol medicines that target the PCSK9 gene. Developers of PCSK9 drugs say they do not share Crooke's concern.
more...
No comment yet.
Scooped by Manu Field
Scoop.it!

PCSK9 and LDL cholesterol | theheart.org

PCSK9 and LDL cholesterol | theheart.org | PCSK9 News | Scoop.it
Among a group of patients treated with atorvastatin who still had elevated cholesterol levels, treatment with the new compound reduced LDL cholesterol by more than 70% from baseline. Researchers called it a.
more...
No comment yet.
Scooped by Manu Field
Scoop.it!

Sanofi sets up cholesterol drug showdown with Amgen | InPharm

Sanofi sets up cholesterol drug showdown with Amgen | InPharm | PCSK9 News | Scoop.it
But whilst behind in the development race, Amgen may have an edge with AMG 145 as it can be injected just once a month, whilst Sanofi's SAR236553 is administered every fortnight. Both drugs are injectable fully human ...
more...
EmmanuelGrunenberger's curator insight, March 11, 2015 8:46 AM

Watch out! the next blockbusters in #dyslipidemia are coming ! #PSCK9 #Sanofi #Amgen

Scooped by Manu Field
Scoop.it!

Amgen's CEO Discusses Q4 2011 Results - Earnings Call Transcript - Seeking Alpha

Amgen's CEO Discusses Q4 2011 Results - Earnings Call Transcript - Seeking Alpha | PCSK9 News | Scoop.it

"We also expect to see data by the end of the year from 4 studies of AMG 145, our fully human antibody directed against PCSK9 that has been shown to lower LDL cholesterol levels in patients with hypercholesterolemia. Our studies explore the efficacy of AMG 145 as monotherapy or in combination with statins in statin-intolerant patients and in patients with heterozygous familial hypercholesterolemia"

more...
No comment yet.
Scooped by Manu Field
Scoop.it!

Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels

Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels | PCSK9 News | Scoop.it

"Taken together our data indicate that PCSK9 secreted by human SMCs is functionally active and capable of reducing LDLR expression in macrophages. A possible direct role for this protein in foam cell formation and atherogenesis is suggested."

more...
No comment yet.
Scooped by Manu Field
Scoop.it!

Rosuvastatin, Proprotein Convertase Subtilisin/Kexin Type 9 Concentrations, and LDL Cholesterol Response: the JUPITER Trial

Journal Club: Rosuvastatin, PCSK9 Concentrations, & LDL Cholesterol Response: the JUPITER Trial (free full text access) http://t.co/sCNhNpU9...
more...
No comment yet.
Scooped by Manu Field
Scoop.it!

Gene Inactivation of PCSK9 Reduces Atherosclerosis in Mice. « Medicine JournalFeeds

more...
No comment yet.
Scooped by Manu Field
Scoop.it!

Regeneron Pharmaceuticals' CEO Presents at the JPMorgan Global Healthcare ... - Seeking Alpha

Regeneron Pharmaceuticals' CEO Presents at the JPMorgan Global Healthcare ... - Seeking Alpha | PCSK9 News | Scoop.it
Regeneron Pharmaceuticals' CEO Presents at the JPMorgan Global Healthcare ...Seeking AlphaWe have a very exciting molecule in our pipeline, our REGN727 for LDL cholesterol lowering which maybe one of the most exciting target in the industry if you...
more...
No comment yet.
Scooped by Manu Field
Scoop.it!

Preliminary results for Sanofi and Regeneron anti-PCSK9 antibody ...

Preliminary results for Sanofi and Regeneron anti-PCSK9 antibody ... | PCSK9 News | Scoop.it
French drug major Sanofi (Euronext: SAN) and USA-based Regeneron (Nasdaq: REGN) have reported positive preliminary results from the Phase II study of their anti-PCSK9 antibody, REGN727/SAR236553 in ...
more...
No comment yet.